StreetAlpha.app
Home › Stocks › GUTS

Fractyl Health, Inc. (GUTS)

$0.97
▼ −2.66%
LAST CLOSE · NOV 17

Fractyl Health develops and sells medical devices, including its Revita device, from Burlington, Massachusetts. It last closed at $0.97 on Nov 17, down 2.66% on the day. The average 12-month price target from 3 analysts is $22.67 (+2247.9% from the last close), with a high of $40.00 and a low of $4.00. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).

AI Auto Pilots
Is GUTS in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$141.0M
Free cash flow
−$90.9M
Valuation
Market cap
$12.8M
13.3M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$31.5M
At Sep 30
Debt
$29.2M
At Sep 30
Shareholder equity
−$13.2M
Shares outstanding
13.3M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $120K$120KFY2023FY2024: $93K$93KFY2024FY2025: $0$0FY2025

From GUTS's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 12).

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
3firms
2 Buy1 Hold0 Sell
Each firm's latest rating on GUTS in the past 90 days
Average 12-month target
$22.67
▲ 2247.9% upside

Based on 3 analysts who set a price target on GUTS in the past 90 days. The average target is $22.67, with a high of $40.00 and a low of $4.00, compared with the last close of $0.97.

Low $4.00Avg $22.67High $40.00
Blue marker: last close $0.97
Highest target$40.00
Average target$22.67
Lowest target$4.00
Latest rating changes
Canaccord GenuityTarget raised
Nov 13Buy$39 → $40
HC Wainwright & Co.Target raised
Nov 13Buy$8 → $24
Canaccord GenuityMaintained
Oct 20Buy$39
Morgan StanleyMaintained
Oct 19Hold$4
Craig-HallumInitiated
Jul 1Buy$4
DateFirmActionRatingPrice target
Nov 13Canaccord GenuityTarget raisedBuy$39 → $40
Nov 13HC Wainwright & Co.Target raisedBuy$8 → $24
Oct 20Canaccord GenuityMaintainedBuy$39
Oct 19Morgan StanleyMaintainedHold$4
Jul 1Craig-HallumInitiatedBuy$4
Loading…

Technical Analysis

GUTS · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock sits between its 20 and 50 day averages. It is 601% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the 20 day average at $0.95, and the nearest resistance the Pivot at $0.97.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 23.2%/day
Key levels
$29.2852 week high+2918.6%
$6.99Swing high (Sep 30)+620.6%
$6.76200 day average+596.9%
$6.23100 day average+542.3%
$3.6050 day average+271.1%
$1.01Pivot R1+4.1%
$0.97Pivot+0.0%
$0.97Last close
$0.9520 day average−2.1%
$0.93Pivot S1−4.1%
$0.82Swing low (Oct 28)−15.5%
$0.8052 week low−17.5%
Indicators
RSI (14)26.11Oversold below 30Oversold
MACD-0.73Above its signal lineBullish
Stochastic55.8Middle of its rangeNeutral
ADX (14)58.0Strong downtrend
Williams %R-40.9Oversold below −80, overbought above −20Neutral
CCI (20)6.0Oversold below −100, overbought above 100Neutral
Rate of change+7.5%Change over 10 sessionsBullish
ATR (14)$0.22Typical daily range, 23.2% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for GUTS

What happened before

See how GUTS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in GUTS in the last 90 days.

Loading…

See today’s whale options flow across the market →

GUTS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲38 buying vs 32 selling
  • ▼Shares held by funds -23.7%
  • ▼Funds holding -4
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding7478−5.1%
In funds' top 1023−33.3%
Held by funds–––
New / increased20 / 1812 / 17+31.0%
Reduced / sold out10 / 2215 / 18−3.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GUTS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GUTS is in one of them and how their past GUTS trades turned out.

GUTS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GUTS in an article yet. Here's the latest on the wider market.

About Fractyl Health

Fractyl Health is a medical device company based in Burlington, Massachusetts. It develops medical devices, including its Revita device, which carries a CE mark and is sold in the European Union and the European Economic Area. The company is also developing product candidates that must receive approval or certification from regulators such as the FDA and European notified bodies before they can be sold. Its products are subject to medical device rules in the EU and the United Kingdom.

Headquarters
Burlington, MA
Founded
2010